BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables outflow grows to $10.69M
Q1 FY2026 accounts payables was $10.69M, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $6.22M.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near $10.69M or moves back toward the trailing-twelve-month quarterly average of $1.55M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.84M) USD
- Year-over-year change
- -1166.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.84M) | -1166.6% |
| FY2024 | 2024-12-31 | 172.52K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Payables vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5837.6% is the highest of 10, against a peer median of -14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $81.11M USD | +53.9% | — | 34.9% | |
| LTM Mar 2026 | $37.94M USD | +15.0% | +57.8% | 18.5% | |
| LTM Aug 2026 | $25.05M USD | +537.3% | — | 3.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $6.22M USD | +5837.6% | — | — |
| LTM Jun 2026 | $6.13M USD | -229.5% | +0.3% | 5.8% | |
| LTM Sep 2026 | $6.02M USD | -14.9% | +69.4% | — | |
| LTM Mar 2026 | $5.1M USD | -58.1% | +0.6% | 3.6% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $3.07M USD | +363.6% | +56.4% | 3.2% |
| LTM Mar 2026 | CHF 1.63M CHF | -62.8% | — | 323.1% | |
| LTM Sep 2026 | $365K USD | -82.6% | — | — | |
| Peer median (excluding BBOT) | — | -14.9% | +56.4% | 5.8% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (74) | (3.52K) | (41.69K) | 7.6M | (134.04M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M |
| Change in Working Capital | 0 | 0 | 15K | (104.61K) | 6.43M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 172.52K | (1.84M) |
| Other Working Capital | 0 | 0 | 15K | (277.13K) | 8.27M |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | (8.53M) | 7.23M |
| Operating Cash Flow | 0 | 0 | (52.08M) | (763.82K) | (113.89M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (606K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (184M) | (83.93M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 157.86M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (184M) | 73.33M |
| Debt Repayment | 0 | 0 | 0 | (209.85K) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 187.25M | 395.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (578.55K) | (12.32M) |
| Financing Cash Flow | 0 | 0 | 0 | 186.46M | 383.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 0 | 225K | 1.7M | 342.84M |
| Free Cash Flow | 0 | 0 | (52.49M) | (763.82K) | (114.5M) |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.